{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:36Z","timestamp":1786982376675,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12325-016-0443-1","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:46:49Z","timestamp":1480639609000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis"],"prefix":"10.1007","volume":"34","author":[{"given":"Rachel","family":"Harrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Messali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi","family":"Azie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"443_CR1","unstructured":"HCUPnet: National and regional estimates on hospital use for all patients from the HCUP National Inpatient Sample (NIS). 2013 [cited 2015 November 30, 2015]. Available from: http:\/\/hcupnet.ahrq.gov\/ ."},{"issue":"121","key":"443_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09059180.00001011","volume":"20","author":"M Kousha","year":"2011","unstructured":"Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20(121):156\u201374.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"443_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","volume":"32","author":"SJ Lin","year":"2001","unstructured":"Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358\u201366.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"443_CR4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijantimicag.2010.08.010","volume":"36","author":"S Perkhofer","year":"2010","unstructured":"Perkhofer S, Lass-Florl C, Hell M, et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and\/or immunosuppressed patients. Int J Antimicrob Agents. 2010;36(6):531\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"443_CR5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909\u201317.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"443_CR6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","volume":"44","author":"A Upton","year":"2007","unstructured":"Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44(4):531\u201340.","journal-title":"Clin Infect Dis"},{"key":"443_CR7","doi-asserted-by":"crossref","unstructured":"Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.","DOI":"10.1186\/s13054-014-0722-7"},{"issue":"5","key":"443_CR8","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1111\/j.1439-0507.2010.01903.x","volume":"54","author":"A Kim","year":"2011","unstructured":"Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011;54(5):e301\u201312.","journal-title":"Mycoses"},{"issue":"1","key":"443_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2008.02.013","volume":"13","author":"KB Tong","year":"2009","unstructured":"Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis. 2009;13(1):24\u201336.","journal-title":"Int J Infect Dis"},{"key":"443_CR10","doi-asserted-by":"crossref","unstructured":"Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26\u201334.","DOI":"10.1046\/j.1524-4733.2002.51108.x"},{"issue":"3","key":"443_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327\u201360.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"443_CR12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","volume":"26","author":"DW Denning","year":"1998","unstructured":"Denning DW. Invasive Aspergillosis. Clin Infect Dis. 1998;26(4):781\u2013803.","journal-title":"Clin Infect Dis"},{"key":"443_CR13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S4244","volume":"1","author":"KP Krueger","year":"2009","unstructured":"Krueger KP, Nelson AC. Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies. Clinicoecon Outcomes Res. 2009;1:35\u201343.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"443_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","volume":"24","author":"M Mikulska","year":"2012","unstructured":"Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice. J Chemother. 2012;24(6):311\u201327.","journal-title":"J Chemother"},{"issue":"6","key":"443_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315.","journal-title":"N Engl J Med"},{"key":"443_CR16","unstructured":"Astellas Pharma U.S. Inc. CRESEMBA\u00ae (isavuconazonium sulfate). 2015; 1\u201328]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500s001,207501s001lbl.pdf ."},{"key":"443_CR17","doi-asserted-by":"crossref","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760\u20139.","DOI":"10.1016\/S0140-6736(15)01159-9"},{"issue":"5","key":"443_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","volume":"170","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291\u2013313.","journal-title":"Mycopathologia"},{"issue":"7","key":"443_CR19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","volume":"19","author":"D Horn","year":"2016","unstructured":"Horn D, Goff D, Khandelwal N, et al. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728\u201334.","journal-title":"J Med Econ"},{"key":"443_CR20","unstructured":"Data on file. Analysis using Premier data to estimate the length of stay for 30-day readmission among patients who were initially hospitalized with invasive aspergillus infection. Astellas Pharma U.S. Inc."},{"key":"443_CR21","unstructured":"Data on file. SECURE trial Clinical Data. Astellas Pharma U.S. Inc."},{"key":"443_CR22","unstructured":"Pfizer I. VFEND (voriconazole) Prescribing Information. 2015 [cited 2015 November 30]. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=618 ."},{"key":"443_CR23","unstructured":"ReadyPrice. 2009 [cited 2016 April 11]. Available from: http:\/\/www.rubali.com\/thomsonreuters\/drug_information\/index.php?frame=ready_price.html ."},{"key":"443_CR24","unstructured":"Consumer Price Index\u2014All Urban Consumers. US Medical Care Services [cited 2016 April 11]. Available from: http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu ."},{"issue":"3","key":"443_CR25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","volume":"55","author":"DR Bickers","year":"2006","unstructured":"Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490\u2013500.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"443_CR26","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","volume":"45","author":"KL Davis","year":"2011","unstructured":"Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17\u201324.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"443_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archdermatol.2007.5","volume":"144","author":"LK Delong","year":"2008","unstructured":"Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35\u20139.","journal-title":"Arch Dermatol"},{"issue":"3","key":"443_CR28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/erp.12.10","volume":"12","author":"X Gao","year":"2012","unstructured":"Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):335\u201343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"443_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00464-012-2430-1","volume":"27","author":"A Johner","year":"2013","unstructured":"Johner A, Raymakers A, Wiseman SM. Cost utility of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Surg Endosc. 2013;27(1):256\u201362.","journal-title":"Surg Endosc"},{"issue":"11","key":"443_CR30","doi-asserted-by":"crossref","first-page":"e003471","DOI":"10.1136\/bmjopen-2013-003471","volume":"3","author":"J Koberlein","year":"2013","unstructured":"Koberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471.","journal-title":"BMJ Open"},{"issue":"5","key":"443_CR31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/gast.2002.32978","volume":"122","author":"RS Sandler","year":"2002","unstructured":"Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500\u201311.","journal-title":"Gastroenterology"},{"issue":"3","key":"443_CR32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3851\/IMP2500","volume":"18","author":"BR Schackman","year":"2013","unstructured":"Schackman BR, Haas DW, Becker JE, et al. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013;18(3):399\u2013408.","journal-title":"Antivir Ther"},{"issue":"3","key":"443_CR33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MAJ.0b013e3181637417","volume":"336","author":"BL Udeh","year":"2008","unstructured":"Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci. 2008;336(3):254\u201364.","journal-title":"Am J Med Sci"},{"key":"443_CR34","unstructured":"Xakellis GC, Frantz R. The cost of healing pressure ulcers across multiple health care settings. Adv Wound Care. 1996;9(6):18\u201322."},{"issue":"4","key":"443_CR35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","volume":"30","author":"J Yu","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379\u201387.","journal-title":"Cornea"},{"issue":"1","key":"443_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00296-003-0392-2","volume":"25","author":"HR Yun","year":"2005","unstructured":"Yun HR, Bae SC. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol Int. 2005;25(1):9\u201314.","journal-title":"Rheumatol Int"},{"issue":"4","key":"443_CR37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archinte.161.4.554","volume":"161","author":"NA Shadick","year":"2001","unstructured":"Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med. 2001;161(4):554\u201361.","journal-title":"Arch Intern Med"},{"issue":"6","key":"443_CR38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/erp.10.69","volume":"10","author":"D Al-Badriyeh","year":"2010","unstructured":"Al-Badriyeh D, Heng SC, Neoh CF, Slavin M, Stewart K, Kong DC. Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):623\u201336.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0443-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:06:00Z","timestamp":1498352760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0443-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0443-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}